Receipt

TECH CENTER 1600/290



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Farb et al.

Application No.: 09/652,345

Application Filing Date: August 31, 2000

Application Title: EFFECT OF STEROIDS ON NMDA RECEPTORS DEPENDS

ON SUBUNIT COMPOSITION

# CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington,

D.C. 20231 on SIGO FARRELL & ASSOCIATES, P.C.

## REQUEST FOR CORRECTION OF FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

Sir:

This paper is filed in response to the Official Filing Receipt issued recently in connection with the subject application. Error(s) were identified in the Official Filing Receipt and corrective action is respectfully requested.

More specifically, prior U.S. Application No. 09/378,547, filed August 20, 1999 was omitted. Please add under "Domestic Priority data as claimed by applicant", ---This application claims benefit of 09/378,547, August 20, 1999.--- Correction of these/this error(s) is respectfully requested. Any deficiency or overpayment should be charged or credited to Deposit Account No. 06-0130.

Respectfully submitted,

Kevin M. Farrell

Attorney for Applicants Registration No. 35,505

(207) 363-0558

Dated: 833\0\

York Harbor, ME 03911



SEP 2 5 2001

United States Patent and Trademark Office WASHINGTON, D.C. 20231

www.uspto.gov

FIL FEE REC'D ATTY.DOCKET.NO **APPLICATION NUMBER** FILING DATE GRP ART UNIT DRAWINGS TOT CLAIMS IND CLAIMS 09/652.345 08/31/2000 1614 873 0146-2026 32 57 6

**CONFIRMATION NO. 2909** 

**UPDATED FILING RECEIPT** 

RECEIVED

MAY 0 3 2001

OC000000006001418°

FARRELL & ASSOCIATES

Date Mailed: 04/24/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER. FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Farrell & Associates, P.C.

York Harbor, ME 03911

P.O. Box 999

David H. Farb, Cambridge, MA; Shelley Russek, Cambridge, MA; Ming-Kuei Jang, Dedham, MA; Terrell Gibbs, Jamaica Plain, MA;

#### Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/151,802 08/31/1999

Foreign Applications

If Required, Foreign Filing License Granted 10/16/2000

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Effect of steroids on NMDA receptors depends on subunit composition

**Preliminary Class** 

514

Data entry by : KIM, JONATHAN

Team : OIPE

Date: 04/24/2001

L TREATMENT AND REAL FROM STORE THE STORE STORE



# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

## **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

# **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

# PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231